15 stories on the wire
Clinical
15 filings Chronological · ET
IMMP
IMMUTEP Narrows Efti Strategy After TACTI-004 Failure, Blames Manufacturing
Immutep traces the failed TACTI-004 trial to structural differences in efti made at 2,000 L scale and refocuses on HNSCC with CPS < 1 and neoadjuvant sarcoma.
a day ago
PRO
IMNN
IMUNON Signs CRADA With National Cancer Institute for IMNN-001
The NCI's Cancer Therapy Evaluation Program will sponsor and fund new trials of IMUNON's DNA-based IL-12 immunotherapy in additional solid tumors.
2 days ago
PRO
EYPT
EYEPOINT Details LUGANO Miss, Says Nine Patients Drove Failed Endpoint
Expanded Phase 3 data show DURAVYU missed non-inferiority in wet AMD overall but hit it when an asymmetric cohort of nine patients is excluded.
2 days ago
PRO
BBIO
BRIDGEBIO Says Oral Infigratinib Cut Ear Infections, Stabilized Sleep Apnea
New exploratory PROPEL 3 data show benefits beyond height growth as BridgeBio awaits FDA review of its achondroplasia drug, with a U.S. launch planned for mid-2027.
3 days ago
PRO
VERU
VERU Pushes Oral Sabizabulin Into Phase 2 for Daraxonrasib-Resistant Pancreatic Cancer
Veru will seek an FDA pre-IND meeting in Q4 2026 after preclinical data showed sabizabulin remains potent in daraxonrasib-resistant pancreatic cancer cells.
4 days ago
PRO
VERU
VERU Pivots Sabizabulin to Pancreatic Cancer After Preclinical Data
Veru will take oral sabizabulin into a planned Phase 2b trial in daraxonrasib-resistant pancreatic cancer and drops its cardiovascular inflammation plan.
4 days ago
PRO
GRI
GRI BIO Presents Phase 2a Biomarker Data on GRI-0621 in IPF at ERS 2026
New translational data from the 35-patient Phase 2a study point to a repair phenotype, with placebo-adjusted FVC of +99 mL at Week 12 and no serious drug-related events.
4 days ago
PRO
PHVS
PHARVARIS Phase 3 Prophylaxis Trial Cuts HAE Attacks by 83%
Deucrictibant XR met the primary endpoint and all secondary endpoints in CHAPTER-3, clearing the way for filings starting in the first half of 2027.
4 days ago
PRO
NVO
NOVO NORDISK Semaglutide Trial in Children Aged 6 to 11 Hits Endpoint
In the STEP Young phase 3 trial, 40.4% of children treated with semaglutide were no longer classified as having obesity after 68 weeks, versus none on placebo.
5 days ago
PRO
TAK
TAKEDA Terminates Phase 3 Soticlestat Study in Dravet and Lennox-Gastaut
Takeda has halted a Phase 3 trial of soticlestat in epilepsy patients previously exposed to fenfluramine, citing a business decision unrelated to patient safety.
8 days ago
PRO
NVO
NOVO NORDISK Completes Phase 3 Trial of CagriSema Against Tirzepatide
The Danish drugmaker's head-to-head Phase 3 study of CagriSema versus Eli Lilly's tirzepatide in type 2 diabetes is now listed as completed.
8 days ago
PRO
Clinical
Spectrum Pharmaceuticals Suspends Phase 3 Poziotinib Trial in HER2 NSCLC
The registry entry for the poziotinib study in HER2 exon 20-mutated lung cancer now reads SUSPENDED, with no patients enrolled and a redesign under discussion with the FDA.
10 days ago
PRO
HRMY
Harmony Biosciences Completes Phase 3 Cannabidiol Trial in Fragile X
The registry entry for Harmony's Phase 3 study of cannabidiol in Fragile X syndrome now shows a status of COMPLETED, updated 1 September 2026.
10 days ago
PRO
INCY
Incyte's Phase 3 Retifanlimab Anal Cancer Trial Listed as Completed
The POD1UM-303/InterAACT 2 study of retifanlimab added to carboplatin-paclitaxel in advanced anal cancer now carries COMPLETED status on ClinicalTrials.gov.
10 days ago
PRO
Clinical
PDS Biotechnology Terminates Phase 3 Trial of PDS0101 in HPV16+ Head and Neck Cancer
PDS Biotechnology has terminated its Phase 3 study of PDS0101 plus pembrolizumab, citing financial constraints rather than safety concerns.
10 days ago
PRO
No filings match.Try another ticker or clear the filter.